Goldman Sachs Maintains Sell on Ginkgo Bioworks Holdings, Lowers Price Target to $1.1
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Matthew Sykes has maintained a Sell rating on Ginkgo Bioworks Holdings (NYSE:DNA) and reduced the price target from $1.25 to $1.1.
January 23, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Goldman Sachs analyst reaffirms Sell rating on Ginkgo Bioworks and decreases price target to $1.1, indicating a bearish outlook.
The reduction in price target by a major financial institution like Goldman Sachs suggests a negative outlook on the stock's performance. This could influence investor sentiment and lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100